SillaJen, Inc. (KOSDAQ:215600)

Market Cap	340.48B
Revenue (ttm)	1.23B
Net Income (ttm)	-25.80B
Shares Out	137.29M
EPS (ttm)	-230.41
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	339,418
Average Volume	449,732
Open	2,500.00
Previous Close	2,480.00
Day's Range	2,465.00 - 2,500.00
52-Week Range	2,340.00 - 5,990.00
Beta	-0.11
RSI	41.47
Earnings Date	Mar 24, 2025

About SillaJen

SillaJen, Inc. develops and commercializes oncolytic immunotherapy products in South Korea. Its lead product is Pexa-Vec for the treatment of advanced liver cancer. The company also develops BAL0891, a dual TTK/PLK inhibitor; SJ-600 to improve the intravenous administration efficiency of anticancer viruses; JX-970 for the treatment of tumor tissues; and JX-900 is a series of modified vaccinia vaccine. SillaJen, Inc. was founded in 2006 and is headquartered in Seoul, South Korea.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2006
• Employees: 37
• Stock Exchange: KOSDAQ
• Ticker Symbol: 215600

Financial Performance

In 2023, SillaJen's revenue was 3.94 billion, a decrease of -21.42% compared to the previous year's 5.01 billion. Losses were -20.37 billion, -17.18% less than in 2022.